Navigation Links
FDA Panel Appears Skeptical Over Key Avandia Data
Date:7/13/2010

By Amanda Gardner
HealthDay Reporter

TUESDAY, July 13 (HealthDay News) During hearings Tuesday into the safety of controversial diabetes drug Avandia, members of the government panel that could decide the drugs' fate seemed skeptical of much of the data presented.

A decision on whether to ban Avandia or not is expected Wednesday.

The hearing has coincided with news that the drug's maker, GlaxoSmithKline, may have buried or manipulated data crucial to Avandia's approval and continued sale.

"Can we trust the sponsor?" Dr. Ellis F. Unger, a U.S. Food and Drug Administration official, asked when referring to GlaxoSmithKline (GSK), The New York Times reported. "I think thats something the committee is going to need to think about here," he said.

Dr. Nancy L. Geller, a member of the FDA advisory committee and director of the Office of Biostatistics Research at the National Heart, Lung and Blood Institute, also made her doubts known, the Times reported. "I'm just concerned about data quality overall," she said.

When told that mortality estimates from clinical trials are generally reliable, Geller replied, "Not if you report the wrong follow-up date and not if you withdraw someone from a trial just before their death."

Things have looked increasingly grim for Avandia this week. In a report released early Tuesday, the Times said that GSK knew more than a decade ago that Avandia caused an increased risk of heart problems but covered up the information.

In a 1999 trial pitting Avandia against its competitor, Actos, the drug company, then known as SmithKline Beecham, found that Avandia posed a heart risk, the newspaper reported.

The Times report, based on internal company documents it obtained, said that the company did not post results of its drug trial findings on its Web site or submit them to federal regulators.

According to a March 29, 2001, e-mail
'/>"/>

Copyright©2010 ScoutNews,LLC.
All rights reserved  

Page: 1 2 3 4

Related medicine news :

1. NJIT professor heads panel studying sudden car acceleration
2. FDA Panel Votes Against Approval of Female Viagra
3. FDA Panel Weighs OK of Female Viagra
4. FDA Panel Backs New Morning After Pill
5. FDA Panel to Vote on New Morning After Pill
6. U.S. Panel Upholds Ban on Gay Men as Blood Donors
7. John Theurer Cancer Center and LLS host panel discussion with leading hematologists
8. DSPanel's New Mobile Analytics Server for Business Intelligence: Data Analysis, Monitoring and Planning When and Where You Need It
9. ANY LAB TEST NOW Launches New Infectious Disease Panels - Affordable Panels Test for H1N1, Staph, E. coli and Other Infectious Diseases
10. PSA-TEC to Present State of the Industry Panel Discussion
11. Panel recommends standardizing prescription container labeling
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Panel Appears Skeptical Over Key Avandia Data
(Date:4/17/2014)... Scientists have identified new pain relief targets that ... pain. BBSRC-funded researchers at King,s College London made ... nerves in the periphery of the body. , ... and identifying mechanisms underlying pain generation and our ... related side effects." , One potential side effect ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
(Date:4/17/2014)... San Diego School of Medicine report that older women, ... major loss are more likely to be compassionate toward ... published in this month,s issue of the International ... are associated with better health and well-being as we ... improve the outcomes of individuals whose deficits in compassion ...
(Date:4/17/2014)... NY In a review published in the April ... president of The Feinstein Institute for Medical Research, says ... medical community,s approach to treating sepsis, which ... Americans. , Sepsis occurs when molecules released into the ... throughout the body. Inflammation is necessary for maintaining good ...
(Date:4/17/2014)... team has created a new technology for modifying ... travel the body and selectively target cancer and ... devices that monitor and modify human physiology is ... no existing technology enabled bioengineers to build such ... respond in a customized fashion. , "The project ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:Study sheds light on how the immune system protects children from malaria 2Health News:The ilk of human kindness 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2
... Lab in Summit County ... Outside of ... a,cardiology testing and treatment facility located in Hudson, was recently,granted accreditation ... Accreditation of Echocardiography,Laboratories (ICAEL)., "We,re thrilled to have this accreditation, ...
... El-Deiry, MD, PhD, Professor of Medicine, Genetics, and Pharmacology ... been pursuing a cancer-targeting molecule called TRAIL and its ... and curtails tumor spread by binding to a specialized ... cancer patients who often have suppressed immunity, and for ...
... Plus PEG-INTRON Improve Efficacy and Lower Relapse Rates, ... the Disease , Higher Dose, Weight-Based Therapy Justified ... 27, 2007) -- As reported recently in the ... 5,000 patients with hepatitis C virus (HCV) showed ...
... VALLEJO, Calif., Dec. 27 Sutter Solano Medical Center,(SSMC) ... Winner. The hospital,was recognized in the Emergency Department (ED) ... scores compared to all,other facilities being measured., The ... achievement in the,health care industry that is bestowed annually, ...
... ALTO, Calif., Dec. 27 Garry W. Rogerson,President and ... the 26th,annual JPMorgan Healthcare Conference in San Francisco on ... A live webcast of the presentation will be publicly ... Go to, http://www.varianinc.com and click on "Investors." An ...
... National Institute of Environmental Health Sciences (NIEHS), part ... a total of $6.8 million for the first ... called DISCOVER - Disease Investigation Through Specialized Clinically-Oriented ... are expected to bridge the gap between basic ...
Cached Medicine News:Health News:Western Reserve Heart Care Receives ICAEL Echocardiography Accreditation 2Health News:Cell-death receptor links cancer susceptibility and inflammation 2Health News:In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment 2Health News:In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment 3Health News:In largest U.S. Hep C trial, researchers determine weight-based dosing is key to optimal treatment 4Health News:Sutter Solano Medical Center Wins National Improvement Award 2Health News:NIEHS awards DISCOVER grants 2Health News:NIEHS awards DISCOVER grants 3
(Date:1/14/2014)... Healthcare Services, Inc. ("DHS"), a portfolio company of GMH Ventures ... Equipment, Inc. ("Progressive") of Clarion, PA ... not disclosed. Progressive is a full service ... sleep, mobility, and respiratory products to customers in the western ...
(Date:1/14/2014)... PLYMOUTH, Minn. , Jan. 14, 2014   NuAire , a ... come to agreement with Hitachi Koki of ... centrifuges in North America . NuAire will utilize ... and Canada to offer assistance ...
(Date:1/14/2014)... 14, 2014 Equashield ( http://www.equashield.com ... drugs, today announced that it has achieved 60% ...   Equashield,s closed systems reduce the ... and other medical professionals who prepare and administer ...
Breaking Medicine Technology:Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Equashield's Sales Grow by 60% in 2013 2
... Dec. 20 The largest study to examine,the ... depression,significantly worsens a patient,s adherence to highly active ... medication,can reverse this outcome, according to a study ... Group Health Cooperative published in the,current online issue ...
... NEW YORK, Dec. 20 Intra-Cellular Therapies, Inc. ... insomnia (SMI) Phase 2,clinical study using its drug ... receptor antagonist and represents an important new,approach to ... separation of 5-HT2A,and dopamine receptor modulatory activities, ITI ...
Cached Medicine Technology:Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment 2Kaiser Permanente - Group Health Study Shows Depression Worsens HIV Treatment 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 2Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 3Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia 4
... The NormoFlow™ System is the only ... during high volume surgical irrigation, especially ... room warm, regardless of length of ... provides safe, consistent performance and is ...
... The Hemokinetitherm is a ruggedly built, simple ... stable temperature for the controlled warming of blood ... This temperature is maintained by a water reservoir ... by a proportional controller which is backed up ...
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... complete anesthesia solution for the MRI environment , ... , ,The Narkomed MRI-2 is the ... VPO monitor, designed and engineered to perform, without ... MRI environments of up to 3.0 Tesla. This ...
Medicine Products: